Transgene is a biotechnology company focused on designing and developing next-generation immunotherapeutics, including a personalized cancer vaccine and multifunctional oncolytic viruses.
A pioneer in viral vector development, we develop promising drug candidates to transform the fight against cancer.
News
- April 12, 2021 - Transgene Announces Upcoming Investor Meetings
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- April 7, 2021 - Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
- April 1, 2021 - Availability of Transgene’s 2020 Universal Registration Document